Online inquiry

IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15844MR)

This product GTTS-WQ15844MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD3E&SSTR2 gene. The antibody can be applied in Cancer research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_000733.4; NM_001050.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 6752
UniProt ID P07766; P30874
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ15844MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4619MR IVTScrip™ mRNA-Anti-LAG3, BMS-986016(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-986016
GTTS-WQ14000MR IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA REGN-3470-3471-3479
GTTS-WQ15004MR IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA SJ25C1 scFv-28Z CAR
GTTS-WQ8302MR IVTScrip™ mRNA-Anti-GLP1R, HM-12525A(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HM-12525A
GTTS-WQ11578MR IVTScrip™ mRNA-Anti-CD276, MG-A271(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MG-A271
GTTS-WQ14347MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA RG7716
GTTS-WQ9507MR IVTScrip™ mRNA-Anti-EGFR, J2898A(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA J2898A
GTTS-WQ14685MR IVTScrip™ mRNA-Anti-MS4A1, SCT-400(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SCT-400
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW